Barbara Weber, M.D., Joins ITM Supervisory Board
Garching / Munich, Germany – ITM Isotope Technologies Munich SE (ITM), a front-runner in the radiopharmaceutical sector, recently announced the election of Barbara Weber, M.D., to its Supervisory Board, starting on May 01. This decision was made during an extraordinary general meeting of the company. With a distinguished career that includes founding Tango Therapeutics (NASDAQ: TNGX), Dr. Weber brings a wealth of experience in biotechnology and pharmaceuticals.
Expertise That Matters
Dr. Weber's impressive track record of over 25 years in various roles, including executive leadership and research, will provide a significant advantage to ITM as it works on its leading Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11). Her extensive knowledge, honed from her time at renowned organizations like Novartis (NYSE: NVS) and GlaxoSmithKline (NYSE: GSK), will be instrumental in propelling ITM's initiatives within the radiopharmaceutical sector.
Vision for Targeted Therapy
Upon her appointment, Dr. Weber expressed her excitement about the potential of targeted radiopharmaceutical therapy in precision oncology. She recognizes the capabilities of this innovative approach to significantly enhance treatment outcomes for cancer patients. "I am eager to collaborate with ITM's Supervisory Board and leadership team as we prepare for an NDA submission for ITM-11 and broaden our pipeline with various targeted radiopharmaceuticals," she stated.
Building on a Strong Foundation
Prior to this role, Dr. Weber served as Senior Vice President of Oncology Translational Medicine at Novartis and as Vice President at GlaxoSmithKline, where she played pivotal roles in obtaining FDA approvals for various oncology drugs. Her deep expertise as a physician-scientist will bring a fresh perspective to ITM, as she has been involved in numerous drug discovery projects aimed at improving cancer treatments.
ITM's Commitment to Innovation
ITM prides itself on its dedication to developing advanced radiopharmaceutical products that cater to patients with hard-to-treat tumors. The company is focused on enhancing the lives of cancer patients through cutting-edge research and innovation in medical radioisotope manufacturing. With Dr. Weber's experience and insight on board, ITM is well-positioned to enhance its existing initiatives.
About ITM Isotope Technologies Munich SE
ITM is committed to delivering a new wave of radiopharmaceutical treatments and diagnostics. The company is focused on addressing the needs of patients and healthcare providers by excelling in the development and global supply of innovative solutions. As part of its mission, ITM continues to progress its precision oncology pipeline, which features multiple Phase 3 studies combining its high-quality radioisotopes with advanced targeting molecules.
For more details, please contact:
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
Frequently Asked Questions
Who is Dr. Barbara Weber?
Dr. Barbara Weber is the President, CEO, and founder of Tango Therapeutics, with over 25 years of experience in the biotech sector.
What is ITM's focus?
ITM focuses on developing radiopharmaceuticals and medical radioisotopes for treating hard-to-treat tumors and improving patient outcomes.
When will Dr. Weber begin her role at ITM?
Dr. Weber will formally assume her role on the Supervisory Board beginning May 01.
What notable companies has Dr. Weber worked at?
Dr. Weber has held key positions at Novartis and GlaxoSmithKline, among others.
What is ITM-11?
ITM-11 is ITM's lead candidate in Phase 3 trials, aimed at improving treatment outcomes in oncology.
